General

BioSpectrum Asia: “Moving forward, cancer may not be a death threat but a manageable disease with strong control”

BioSpectrum Asia: “Moving forward, cancer may not be a death threat but a manageable disease with strong control”

Cartherics’ CEO, Prof. Alan Trounson was recently interviewed by BioSpectrum Asia discussing the development of the company’s cell-based immunotherapies for cancer treatment. The article discusses:

The advantages of using iPSCs from cord blood for creating ‘off-the-shelf’ CAR-NK and CAR-T therapies.
How Cartherics’ lead product, CTH-401 differentiates itself as the only NK cell product developed specifically […]

Christine Filippis2024-11-06T14:23:22+11:00November 6th, 2024|

Cartherics is “Frocking Up” this month to support ovarian cancer research

Cartherics is “Frocking Up” this month to support ovarian cancer research

Cartherics is frocking up this October to raise funds and awareness for crucial ovarian cancer research. The current five-year survival rate for ovarian cancer patients is just 49%. There is no early detection test and treatment options haven’t improved significantly in decades.

Cartherics’ Board Advisor and ovarian cancer survivor Heather Hawkins said, “As a survivor, I hope to […]

Christine Filippis2024-10-30T15:45:51+11:00October 30th, 2024|

Cartherics raises over $15 Million in oversubscribed private financing round to advance cell therapy programs

Cartherics raises over $15 Million in oversubscribed private financing round to advance cell therapy programs

Financing round was significantly oversubscribed by existing investors and new private investors.

Funding will enable the Company to progress clinical trials of its lead CAR-NK cell therapy product, CTH-401, in ovarian cancer and expand its pipeline to additional disease indications.

Melbourne, Australia, 1 October 2024 –  Cartherics Pty Ltd (“Cartherics” or “Company”), a […]

Christine Filippis2024-10-01T09:27:29+10:00October 1st, 2024|

Cartherics’ CEO named ScholarGPS highly ranked scholar for outstanding scholarly contributions

Cartherics’ CEO named ScholarGPS highly ranked scholar for outstanding scholarly contributions

We are pleased to announce that Cartherics’ CEO, Prof. Alan Trounson has been recognised as a ScholarGPS Highly Ranked Scholar in recognition of his exceptional scholarly performance. His impactful work and high-quality contributions have earned him a spot in the top 0.05% of 30 million scholars globally, ranking highly across seven fields. Notably, Alan is […]

Christine Filippis2024-09-20T11:35:17+10:00September 20th, 2024|

Breakthrough FDA approval for first solid tumor cell therapy signals new era for cancer treatment

Breakthrough FDA approval for first solid tumor cell therapy signals new era for cancer treatment

Exciting advancements are on the horizon for cancer treatment. Earlier this year, the FDA approved Lifileucel, an autologous tumor infiltrating lymphocyte (TIL) product for the treatment of melanoma. A recent article published in Drug Discovery and Development by Cartherics’ Prof. Alan Trounson and Dr. Ian Nisbet discusses how this approval marks a significant milestone in […]

Christine Filippis2024-08-08T10:13:33+10:00August 8th, 2024|

Cartherics enters agreements with UniQuest, The University of Queensland and The University of Sydney for advancing innovative cardiac cellular therapy

Cartherics enters agreements with UniQuest, The University of Queensland and The University of Sydney for advancing innovative cardiac cellular therapy

Cartherics, UniQuest and The University of Sydney enter Technology Licence Agreement for Cartherics’ iPSC cell line.
Cartherics, The University of Queensland and The University of Sydney enter Material Transfer Agreement to support development of iPSC-derived cardiomyocytes for the treatment of cardiovascular disease.

Melbourne, Australia, 25 July 2024 – Cartherics Pty Ltd (“Cartherics” or “Company”), […]

Christine Filippis2024-07-25T13:12:43+10:00July 25th, 2024|

Innovative Cancer Solutions: Cartherics’ Patented Immunotherapy Approach

Innovative Cancer Solutions: Cartherics’ Patented Immunotherapy Approach

In a recent interview with Wholesale Investor, Cartherics’ COO, Dr Ian Nisbet shares deep insights into the company’s groundbreaking work in developing cell therapy treatments for cancer. He discusses Cartherics’ expanding intellectual property portfolio, the impact of targeting TAG-72 on treating ovarian and gastric cancers as well as recent collaborations and the growing market for […]

Christine Filippis2024-06-14T16:20:03+10:00June 14th, 2024|

Cartherics secures Australian patent for innovative cancer cell therapy

Cartherics secures Australian patent for innovative cancer cell therapy

Melbourne, Australia, 12 June 2024 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has been granted its first Australian patent, AU2016361451, entitled “Genetically modified cells and uses thereof”, providing patent support for multiple development candidates in the […]

Christine Filippis2024-06-12T13:49:21+10:00June 12th, 2024|

Cartherics granted European patent for multiple development candidates

Cartherics granted European patent for multiple development candidates

Melbourne, Australia, 23 May 2024 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has been granted its second European Patent from the family represented by the international patent filing WO2017088012.

The European Patent No. 3708587 B1, titled ‘Genetically […]

Christine Filippis2024-05-23T15:21:41+10:00May 23rd, 2024|

Addressing solid tumours and the upcoming clinical trial of natural killer (NK) cell therapy for ovarian cancer

Addressing solid tumours and the upcoming clinical trial of natural killer (NK) cell therapy for ovarian cancer

Cartherics’ CEO, Prof. Alan Trounson AO recently presented at Private Capital 2024 held at the ASX Building in Sydney. During his presentation, Alan delves into Cartherics‘ pioneering technology

Christine Filippis2024-06-14T15:02:52+10:00May 22nd, 2024|

About us

Sign up to our newsletter